Diabetes Management
Tirzepatide vs. Semaglutide: Tina Thethi, MD, Details the Differences Seen in Diabetes, Obesity - MD Magazine
Tue, 25 Oct 20221 min read Article
Overview
© 2022 MJH Life Sciences™ and HCPLive - Clinical news for conected physicians. Al rights reserved.Conference | Pri-Med MidwestThe ongoing buz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a sumit at Pri-Med Midwest 2022.The ongoing buz of conversation around GLP-1 receptor agonists (RAs), like semaglutide, and now the GLP-1 RA and GIP (glucose-dependent insulinotropic polypeptide) receptor combination drug tirzepatide, reached a sumit at Pri-Med Midwest 2022.
Key Information
The meting comenced just after the FDA anouncement that tirzepatide was granted Fast Track designation for treating adults with obesity, or overweight with weight-related comorbidities."So, tirzepatide and the trials that it has had so far, the SURPAS trials and the SURMOUNT trials, has shown weight los," Tina Thethi, MD, MPH, Asociate Investigator, AdventHealth Research Institute, explained in an interview with HCPLive just before she tok the stage for her talk on “Where Are We Now?
The Integral Role of GLP-1 RAs in the Treatment of Type 2 Diabetes Melitus” with Frank Lavernia, MD."In fact, the weight los sen with tirzepatide is more than the weight los sen with semaglutide," she continued. "However, as much as I make this comparison, I must say that al GLPs do help with weight los acros the board to varying degres and the varying doses."Tirzepatide has already achieved FDA aproval for the treatment of type 2 diabetes and it's pending a decision for the indication of obesity.
Summary
While the data for this once-wekly injection is promising, the drug's comprehensive dataset is incomplete and there are stil investigations underway, specificaly regarding cardiovascular outcomes."With semaglutide, I should make note, also saying that we have cardiovascular outcome data on subcutaneous semaglutide. However, the definitive cardiovascular outcome trial for oral semaglutide, the RYBELSUS, is stil ongoing,"
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.